Cerebral metabolism & blood flow
One of 6 mechanistic pathways to 🧠 Focus, memory & cognition · 19 options
The brain is 2% of body weight and 20% of resting energy use. Brain fog is very often a fuel and perfusion problem rather than a neurotransmitter one, and it responds to a completely different set of tools.
The brain is 20% of resting energy use, and cerebral perfusion follows the same vascular rules as the heart. Raised ApoB and HbA1c predict cognitive decline decades ahead — this is the most actionable pathway here and the least exciting.
HbA1c (Hemoglobin A1c)Lipid Panel (Cholesterol, HDL, LDL, Triglycerides)ApoB (Apolipoprotein B)HomocysteineCoenzyme Q10🧠 Cognitive Decline & Alzheimer's Risk covers these in one panel →
What engages this pathway
Ordered by how directly each one acts on the mechanism above — never by how much trial evidence exists. Each links to its full breakdown with dosing, half-life and vendor.
💉 Methylene Blue
At low dose it accepts and donates electrons in the mitochondrial chain, bypassing damaged complexes and raising cerebral ATP. Human imaging studies show increased cerebral blood flow and improved memory task performance. Contraindicated with serotonergics and in G6PD deficiency.
💉 J-147
A curcumin-derived molecule that is not curcumin, selected in aging-brain models rather than amyloid ones. Its target turned out to be mitochondrial ATP synthase: inhibit it modestly and an adaptive stress response follows, raising mitochondrial calcium buffering and, downstream, NGF and BDNF. The mouse work is striking and no human trial has reported.
💉 Nad+
Neurons are metabolically demanding and NAD+ declines with age. Restoring the pool is upstream of essentially all neuronal energy metabolism.
💉 Actovegin
Improves cellular glucose and oxygen uptake; used in European practice for cerebrovascular insufficiency.
💉 Cerebrolysin
Neurotrophic plus metabolic — improves cerebral glucose utilization in imaging studies.
🧬 Vinpocetine
Increases cerebral blood flow selectively without stealing from other regions, and improves erythrocyte deformability. European clinical use for cognitive impairment.
🧬 Ginkgo Biloba
Improves microcirculation and has antiplatelet activity. The GEM trial found it does not prevent dementia — but that null result says nothing about acute cognitive effects in healthy adults, which is a different question.
🧬 Acetyl-L-Carnitine
Crosses into the brain, supports mitochondrial fatty-acid oxidation and acts as an acetyl donor for acetylcholine synthesis. Trial evidence in age-related cognitive decline and neuropathy.
🧬 CoQ10
Electron transport chain component; deficiency impairs neuronal energy production. Statin users are a specific at-risk group.
🧬 Creatine
Brain phosphocreatine buffers ATP. Trials show cognitive benefit specifically under sleep deprivation and in vegetarians, whose baseline brain creatine is lower — again, a mechanistically coherent responder pattern.
🧬 PQQ
Mitochondrial biogenesis in neurons; small Japanese trials suggest cognitive benefit.
🧬 D-Ribose
A pentose sugar feeding the ATP salvage pathway. The theoretical case is faster ATP repletion in an energy-depleted cell; trials in healthy people have been largely null, and what signal exists is in fatigue and cardiac states.
🧬 Benfotiamine
Fat-soluble B1 that reaches the brain. Thiamine deficiency causes severe and rapid cognitive impairment; this form corrects it far more effectively than thiamine HCl.
🧬 Nitrosigine
Human trials show improved blood flow and cognitive performance — the perfusion argument with actual data behind it.
💉 Idebenone
A short-chain coenzyme Q10 analog — ten carbons of tail where Q10 has fifty, which is what buys the absorption Q10 lacks. Reduced by NQO1, it feeds electrons to complex III and bypasses complex I, which is why its one approval is in a complex I disease. Read the dose before anything else: that approval is 900mg a day in three divided doses and the capsules sold as a nootropic are 30mg. Its mechanism also predicts less effect the healthier the mitochondria.
💉 Nicergoline
Prescription-only in Europe and Asia and never approved in the US, so there is no FDA label behind any claim made for it. Sold for fifty years on alpha-1 blockade and cerebral blood flow; the most modern measurement of it is blockade of the human 5-HT3A receptor, which is neither. It is an ergoline, and the class hazard is valvular and retroperitoneal fibrosis through 5-HT2B — an affinity nobody has published for this member.
💉 Hopantenic Acid
Pantothenic acid with the beta-alanine swapped for GABA, sold as Pantogam, Pantogam Activ and Pantocalcin — which are two different isomeric compositions, not three brands of one drug. Two Russian multicenter double-blind placebo-controlled trials exist and both are in children; no controlled trial has been run in a healthy adult. The safety point nobody states: the calcium salt produced a five-patient series of acute encephalopathy with metabolic acidosis and hypoglycemia, through competition with vitamin B5 for coenzyme A.
💉 Pyritinol
Two vitamin B6 molecules joined by a disulfide — and that bond makes it a thiol drug rather than a vitamin, in the chemical family of penicillamine and tiopronin. The randomized trial that resolves cleanly is null, in newborns after birth asphyxia; its other randomized appearance is a hangover review that rated all evidence very low quality. Liver enzymes are the measurement worth having, because cholestatic injury is the documented thiol-drug reaction.
💉 CMS-121
The metabolic half of the same mechanism. Blocking the first committed step of lipogenesis leaves acetyl-CoA unspent, and in rapidly aging mice that pool showed up as increased histone H3K9 acetylation — a site the authors link to memory enhancement — plus preserved mitochondrial homeostasis. The prediction is a brain that runs its fuel differently, not a brain with more blood flow, and the readout used in mice was protein and metabolite levels rather than perfusion.
What actually decides this outcome, in order of size
Brain fog is a symptom with at least four unrelated causes, and this page addresses one of them. Ranked by how much of the outcome each one owns:
- Whether the problem is fuel and perfusion at all, because the alternatives are more common. Short sleep, an untreated thyroid problem, iron deficiency and low B12 all present as this, and all four are on one requisition. A perfusion agent given to somebody with a ferritin of eight is a category error with a cost.
- What has actually been measured in a human brain, because almost nothing on this page has been. The acute effects of methylene blue on cerebral blood flow and metabolism have been measured in humans Singh 2023, and its interaction with the respiratory chain has been characterized Svab 2021. That is the reference point. Every other perfusion claim on this page is inferred from peripheral measurements or from animal work.
- Whether the question is prevention or acute performance, because a famous null answered only the first. Ginkgo did not prevent dementia in a large randomized trial DeKosky 2008 and did not slow cognitive decline in the same program Snitz 2009. Those are prevention endpoints in older adults over years. They say nothing about an acute effect on attention in a healthy adult, which is a different question that those trials were not built to answer.
- Your baseline substrate status, because the responders in the creatine literature are the ones who started low. Brain phosphocreatine buffers ATP, the effects on brain function and health have been reviewed Forbes 2022 Candow 2023, and the reproducible signals are in sleep deprivation and in people with lower baseline brain creatine. That is a responder pattern rather than a general claim.
- Which interactions you are walking into, because two items here have serious ones. Methylene blue is a monoamine oxidase inhibitor at relevant doses: perioperative serotonin syndrome has been reported Huang 2022 and the prevalence of serotonergic drug use in patients exposed to it has been surveyed McMillan 2025. Ginkgo affects bleeding risk and coagulation Mai 2025 and ginkgotoxin can precipitate seizures through pyridoxine antagonism Jang 2015.
- The rest of the shelf, last, and its evidence is mostly in deficit states rather than in healthy adults. Acetyl-L-carnitine has a meta-analysis of double-blind randomized trials in mild cognitive impairment and Alzheimer disease Montgomery 2003 and a critical update Pennisi 2020; D-ribose sits in heart failure and fatigue narratives rather than in healthy cognition Krueger 2021; coenzyme Q10 has a trial in statin-associated asthenia in older adults Fogacci 2024.
The order to run these in, and what has to be true first
Exclude the common causes, correct the substrate, then try one perfusion agent at a time. The ordering principle is prevalence: the boring causes are the likely ones.
- One requisition first. Complete Blood Count (CBC) with Differential with Ferritin, Vitamin B12 with Folate, RBC and Homocysteine, TSH (Thyroid-Stimulating Hormone) with Free T4 (Thyroxine), HbA1c (Hemoglobin A1c), Vitamin B1 (Thiamine) and Vitamin D (25-Hydroxy). Thiamine is on the list because its deficiency causes rapid and severe cognitive impairment and is reversible if caught.
- Sleep before any purchase, because the creatine evidence is clearest under sleep deprivation and the reason is that sleep loss is the exposure Forbes 2022. What's keeping you awake — the upstream causes is the page for that, and it is free.
- Creatine first among the supplements, because it is cheap, safe and has a defined responder group. Brain phosphocreatine is the mechanism Candow 2023, and the honest expectation is a small effect that is largest in vegetarians and in the sleep-deprived Forbes 2022.
- Benfotiamine and Acetyl-L-Carnitine next, as substrate arguments with different evidence. Benfotiamine reaches the brain more effectively than thiamine hydrochloride; acetyl-L-carnitine has a meta-analysis in cognitive impairment Montgomery 2003 and a critical update that is worth reading for what it does not support Pennisi 2020.
- Nitrosigine and Ginkgo Biloba are the perfusion arm, and the second has a bleeding interaction. Ginkgo's prevention nulls are real and specific DeKosky 2008 Snitz 2009; its coagulation effect is a practical contraindication alongside anticoagulants Mai 2025 and its seizure risk sits with pyridoxine antagonism Jang 2015.
- Methylene Blue only with the interaction list checked and G6PD status considered. It is the compound here with human cerebral blood flow and metabolism measurements Singh 2023 and the compound here most capable of causing harm: serotonin syndrome has been reported perioperatively Huang 2022 and exposure alongside serotonergic drugs is common enough to have been surveyed McMillan 2025.
- CoQ10 if statins are in the picture, on a specific population argument rather than a general one. A trial exists in statin-associated asthenia in older adults Fogacci 2024, which is a much narrower claim than the one usually made for it.
- Actovegin, Cerebrolysin and Vinpocetine are the European clinical end and are last. Actovegin has a large randomized trial in post-stroke cognitive impairment Guekht 2017 and an unidentified active fraction, which is an unusual combination. Vinpocetine is not something to take when pregnancy is possible.
What gets bought for this that cannot move it
The category that fails structurally is the nootropic stack bought without the requisition. Four common and cheap-to-exclude conditions produce exactly this symptom, and none of them responds to a perfusion agent. That is not a hedge; it is the highest-probability path to actually fixing the complaint, and it is the step people skip because it involves a needle rather than a bottle.
The surrogate here is cerebral blood flow, and it is a good measurement being asked to do a job it cannot. Perfusion has been measured in humans for one compound on this page Singh 2023; everything else infers it. And a change in flow is not a change in cognition: the brain autoregulates, more blood does not automatically mean more work done, and the trials that used cognitive endpoints in older adults over years produced nulls DeKosky 2008 Snitz 2009. A product with a flow story and no cognitive endpoint has told you about a mechanism and not about a result.
The most dangerous item on the page is also the best measured. Methylene blue is a monoamine oxidase inhibitor at doses people take, which is why serotonin syndrome has been reported in the perioperative setting Huang 2022 and why the overlap with serotonergic prescriptions has been quantified McMillan 2025. Anyone on an antidepressant should treat this compound as contraindicated until a prescriber says otherwise, and G6PD deficiency is a separate and independent reason to avoid it.
If the goal underneath is different, so is the page. If the problem is attention and drive rather than fuel, Catecholamine & dopaminergic drive is where Modafinil and Armodafinil sit and it is a different pharmacology entirely. If it is encoding and recall, Cholinergic — attention, encoding & recall holds Piracetam. If it is inflammation, Neuroinflammation & membrane integrity. And sudden cognitive change, new weakness, or a change in speech is an emergency assessment rather than a supplement question.
How you would know it was working, on a real read-out and a real timescale
This page makes two predictions. The requisition will explain the symptom outright in a meaningful minority of readers, which no product here can match; and anything acting through perfusion declares itself acutely rather than over months, so a four-week trial is enough for that arm and is not enough for the substrate arm.
- Ferritin, Vitamin B12 with Folate, RBC, TSH (Thyroid-Stimulating Hormone) and HbA1c (Hemoglobin A1c) at baseline. These are the exclusions. Repeat only what was abnormal, at 12 weeks, because both the iron store and red cell folate integrate over months.
- Homocysteine once, with the B12 and folate. It is the functional read-out of that cycle and it is raised before the individual vitamin levels become unambiguous.
- Vitamin B1 (Thiamine) if there is any history of heavy alcohol use or poor intake. Thiamine deficiency is the one cause on this list where delay costs something permanent, and it is treated rather than monitored.
- Complete Blood Count (CBC) with Differential before Methylene Blue, and the full medication list before it. The blood count is context; the medication list is the actual safety step, because the serotonergic overlap is the documented hazard McMillan 2025 Huang 2022.
- A repeated timed cognitive task, same time of day, same conditions, weekly. A trail-making test or a fixed n-back. This is the endpoint the trials used DeKosky 2008 and the only one that distinguishes feeling sharper from being faster.
What will fool you. Cognitive tasks improve with practice for several sessions, so the first three runs are learning rather than effect. Caffeine timing changes any afternoon test more than anything on this page does. Sleep the night before dominates every measurement here, which is why the task is repeated weekly rather than once. Methylene blue is intensely colored and cannot be blinded in a personal trial, and it turns urine blue-green, which is a strong expectancy cue Singh 2023. Ginkgo's prevention nulls do not settle the acute question and its bleeding interaction is real regardless Mai 2025. And an unstandardized botanical extract is standardized to a marker rather than to activity.
Sources read for these sections
- Singh N, et al. The effects of acute Methylene Blue administration on cerebral blood flow and metabolism in humans and rats. Journal of Cerebral Blood Flow and Metabolism 2023 · PMID 36803299
- Svab G, et al. Methylene Blue Bridges the Inhibition and Produces Unusual Respiratory Changes in Complex III-Inhibited Mitochondria. Studies on Rats, Mice and Guinea Pigs. Antioxidants (Basel) 2021 · PMID 33669457
- McMillan E, et al. Prevalence of Serotonergic Drug Use in Patients Exposed to Perioperative Methylene Blue: A Cross-Sectional Study. Cureus 2025 · PMID 40271333
- Huang WH, et al. Postoperative Serotonin Syndrome Following Administration of Preoperative Intrapulmonary Methylene Blue and Intraoperative Granisetron: A Case Report. American Journal of Case Reports 2022 · PMID 35619329
- DeKosky ST, Williamson JD, et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA 2008 · PMID 19017911
- Snitz BE, O'Meara ES, et al. Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial. JAMA 2009 · PMID 20040554
- Mai NTQ, et al. Impact of Ginkgo biloba drug interactions on bleeding risk and coagulation profiles: A comprehensive analysis. PLoS One 2025 · PMID 40198642
- Jang HS, et al. Ginkgotoxin Induced Seizure Caused by Vitamin B6 Deficiency. Journal of Epilepsy Research 2015 · PMID 26819944
- Pennisi M, et al. Acetyl-L-Carnitine in Dementia and Other Cognitive Disorders: A Critical Update. Nutrients 2020 · PMID 32408706
- Montgomery SA, et al. Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease. International Clinical Psychopharmacology 2003 · PMID 12598816
- Forbes SC. Effects of Creatine Supplementation on Brain Function and Health. Nutrients 2022 · PMID 35267907
- Candow DG. “Heads Up” for Creatine Supplementation and its Potential Applications for Brain Health and Function. Sports Med 2023 · PMID 37368234
- Krueger KJ. Mitochondrial bioenergetics and D-ribose in HFpEF: a brief narrative review. Ann Transl Med 2021 · PMID 34805366
- Fogacci F, et al. Effect of Coenzyme Q10 on Physical Performance in Older Adults with Statin-Associated Asthenia: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial. Journal of Clinical Medicine 2024 · PMID 38999304
- Guekht A, Skoog I, Edmundson S, Zakharov V, Korczyn AD. ARTEMIDA Trial (A Randomized Trial of Efficacy, 12 Months International Double-Blind Actovegin): A Randomized Controlled Trial to Assess the Efficacy of Actovegin in Poststroke Cognitive Impairment. Stroke 2017;48(5):1262-1270 · PMID 28432265
The other 5 routes to focus, memory & cognition
Pick the pathway that matches where you are actually stuck. An appetite drug does nothing for someone who already undereats.
You know the goal. Skool has the plan.
This pathway is one arm of The Focus, memory & cognition Blueprint. The members' version has where this arm sits in the sequence, what to stack it with, and the markers that tell you to keep going or stop.
Open The Focus, memory & cognition Blueprint in Skool →$10/mo, cancel anytime.
← Open this pathway in the interactive Vault
Frequently asked questions
The brain is 2% of body weight and 20% of resting energy use. Brain fog is very often a fuel and perfusion problem rather than a neurotransmitter one, and it responds to a completely different set of tools.
19 options are mapped to this pathway in the Vault, including Methylene Blue, J-147, Nad+, Actovegin. They are grouped by the mechanism they act through rather than ranked by how much trial evidence exists — 11 carry clinical validation and 7 are mechanistic predictions.
The brain is 20% of resting energy use, and cerebral perfusion follows the same vascular rules as the heart. Raised ApoB and HbA1c predict cognitive decline decades ahead — this is the most actionable pathway here and the least exciting. The markers worth checking are HbA1c (Hemoglobin A1c), Lipid Panel (Cholesterol, HDL, LDL, Triglycerides), ApoB (Apolipoprotein B), Homocysteine.
Unproven is not the same as ineffective. Of the 19 options on this pathway, 11 have clinical validation and 7 are graded theoretical — meaning the mechanism is sound but the specific human trial has not been run, which is true of a great deal of what works in this space. Nothing on this page is ordered by evidence tier, because sorting by trial count would bury the compounds you came looking for.
Where this goes next
Everything above is the free case for Cerebral metabolism & blood flow. The protocol — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.